Global Donafenib Tosylate Market Strategic Research Report

Scope of the Report

The global Donafenib Tosylate market size is predicted to grow from US$ 34.63 million in 2025 to US$ 93.74 million in 2032; it is expected to grow at a CAGR of 6.2% from 2026 to 2032.

In 2025, global production of donafenib tosilate reached approximately 32,000 units.Donafenib Tosylate is an orally administered small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of malignant tumors such as hepatocellular carcinoma. It is the tosylate form of donafenib and exerts its effects by inhibiting multiple kinases associated with tumor growth and angiogenesis, including RAF kinases, VEGFR, and PDGFR, thereby blocking tumor cell proliferation and tumor angiogenesis.

Compared with traditional drugs of the same class, donafenib tosylate maintains antitumor activity while achieving improved safety and tolerability to a certain extent through structural optimization. As one of the domestically developed targeted anticancer drugs in China, it has been approved for first-line treatment of advanced hepatocellular carcinoma and demonstrates significant clinical value and promising development prospects.

Donafenib Tosylate, as a domestically developed small-molecule multi-target tyrosine kinase inhibitor in China, is primarily positioned in the hepatocellular carcinoma (HCC) treatment market. Globally, the incidence and mortality of liver cancer remain high, particularly in Asia-Pacific regions such as China, where the large patient population provides a stable and continuously growing market demand for this drug. From a competitive perspective, targeted therapies such as sorafenib and lenvatinib have already captured a certain market share; however, with increasing clinical demands for improved efficacy and safety, next-generation drugs are gaining attention. Clinical studies have demonstrated that donafenib tosylate offers favorable survival benefits and tolerability, giving it a competitive advantage in the first-line treatment setting.

In the Chinese market, government support for innovative drugs, improvements in reimbursement access, and the implementation of centralized procurement policies are expected to enhance drug accessibility and promote market penetration. Meanwhile, with the advancement of precision medicine and the continuous standardization of clinical treatment practices, targeted therapies with differentiated advantages are more likely to gain acceptance among physicians and patients. From a global perspective, the demand for targeted cancer therapies continues to grow; however, entry into mature markets such as Europe and the United States will still require further clinical evidence and regulatory approvals.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Donafenib Tosylate market?

What factors are driving Donafenib Tosylate market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Donafenib Tosylate market opportunities vary by end market size?

How does Donafenib Tosylate break out by Type, by Application?

This report presents a comprehensive overview of the global Donafenib Tosylate market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 200 mg
• 300 mg

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Dosage Form

• Tablets
• Powder

Segment by Application

• Hepatocellular Carcinoma (HCC)
• Inhibit tumor Cell Proliferation
• Inhibit tumor Angiogenesis
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Donafenib Tosylate market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hepatocellular Carcinoma (HCC), Inhibit tumor Cell Proliferation, Inhibit tumor Angiogenesis evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact